TMCI vs JNJ vs SYK vs ZBH vs BSX

For growth investors, Boston Scientific Corporation (BSX) is the stronger pick with 19.

9% revenue growth year-over-year, versus 1. 6% for Treace Medical Concepts, Inc. (TMCI). Zimmer Biomet Holdings, Inc. (ZBH) offers the better valuation at 23. 2x trailing P/E (9. 7x forward), making it the more compelling value choice. Analysts rate Johnson & Johnson (JNJ) a "Buy" — based on 40 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Zimmer Biomet Holdings, Inc.

(ZBH) is the cheapest at 23. 2x versus Johnson & Johnson at 38. 2x. On forward P/E, Zimmer Biomet Holdings, Inc. is actually cheaper at 9. 7x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Stryker Corporation wins at 1. 28x versus Johnson & Johnson's 34. 02x — a reasonable growth-adjusted valuation.

Over the past 5 years, Johnson & Johnson (JNJ) delivered a total return of +43.

9%, compared to -93. 9% for Treace Medical Concepts, Inc. (TMCI). Over 10 years, the gap is even starker: SYK returned +179. 2% versus TMCI's -92. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Johnson & Johnson (JNJ) is the lower-risk stock at 0.

04β versus Treace Medical Concepts, Inc. 's 2. 19β — meaning TMCI is approximately 4789% more volatile than JNJ relative to the S&P 500. On balance sheet safety, Treace Medical Concepts, Inc. (TMCI) carries a lower debt/equity ratio of 16% versus 66% for Stryker Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Boston Scientific Corporation (BSX) is pulling ahead at 19.

9% versus 1. 6% for Treace Medical Concepts, Inc. (TMCI). On earnings-per-share growth, the picture is similar: Boston Scientific Corporation grew EPS 55. 2% year-over-year, compared to -57. 8% for Johnson & Johnson. Over a 3-year CAGR, BSX leads at 16. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Johnson & Johnson (JNJ) is the more profitable company, earning 15.

8% net margin versus -27. 7% for Treace Medical Concepts, Inc. — meaning it keeps 15. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JNJ leads at 24. 9% versus -25. 5% for TMCI. At the gross margin level — before operating expenses — TMCI leads at 79. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Stryker Corporation (SYK) is the more undervalued stock at a PEG of 1. 28x versus Johnson & Johnson's 34. 02x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Zimmer Biomet Holdings, Inc. (ZBH) trades at 9. 7x forward P/E versus 19. 1x for Johnson & Johnson — 9. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BSX: 69. 3% to $91. 33.

In this comparison, JNJ (2.

2% yield), SYK (1. 2% yield), ZBH (1. 2% yield) pay a dividend. TMCI, BSX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Johnson & Johnson (JNJ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

04), 2. 2% yield, +131. 3% 10Y return). Treace Medical Concepts, Inc. (TMCI) carries a higher beta of 2. 19 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JNJ: +131. 3%, TMCI: -92. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: TMCI is a small-cap quality compounder stock; JNJ is a large-cap quality compounder stock; SYK is a mid-cap quality compounder stock; ZBH is a mid-cap quality compounder stock; BSX is a mid-cap high-growth stock. JNJ, SYK, ZBH pay a dividend while TMCI, BSX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.